Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trialThomas Engstrøm, Lars Køber, Jens Aarøe et al.|The Lancet|2015Cited by 966
Risk factors of late cardiogenic shock and mortality in ST-segment elevation myocardial infarction patientsLaust Emil Roelsgaard Obling, Christian Hassager, Martin Frydland et al.|European Heart Journal Acute Cardiovascular Care|2017Cited by 71
Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trialAlexandra J. Lansky, Andreas Baumbach, William Wijns et al.|The Lancet|2018Cited by 61
Lactate is a Prognostic Factor in Patients Admitted With Suspected ST-Elevation Myocardial InfarctionMartin Frydland, Christian Hassager, Jacob Eifer Møller et al.|Shock|2018Cited by 56
Prehospital Pulse-Dose Glucocorticoid in ST-Segment Elevation Myocardial InfarctionJasmine Melissa Madsen, Jacob Thomsen Lønborg, Thomas Engstrøm et al.|JAMA Cardiology|2024Cited by 18